DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”
17 Mai 2023 - 6:49PM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the launch of “IRIS-ai
powered by DIAGNOS” by IRIS, The Visual Group, in partnership with
DIAGNOS.
For over two years, IRIS and DIAGNOS have joined
forces to advance and combine technological innovations and provide
front-line clinical experience to improve patient care through
early detection and follow-up of various ocular diseases, with the
training of DIAGNOS algorithms and with the help of annotations
from 30 IRIS optometrists. A total of 14,000 patients across Quebec
were screened, generating a comprehensive databank with images of
patients across the province, reflecting the diversity of patients
in Quebec.
"At IRIS, we believe that delivering the best
optometric service to our patients is achieved through an
unwavering commitment to innovation and research. We are proud to
not only invest significant financial resources but also in our
investment in human expertise, to remain at the forefront of our
field, and to continue to offer top quality optometric care,"
states Éric Babin, President of IRIS.
Under the Quebec Ministry of Economy, Innovation
and Energy's INVEST-AI initiative, a pilot program was submitted by
the two partners in 2020, followed by a subsidy to adapt the AI
technology in a commercial context one year later. Participating
IRIS optometrists contributed their clinical expertise by
validating the analyses of the algorithms, ensuring their relevance
and accuracy.
"For us, it was essential to partner with a
company that not only attaches importance to a rigorous and precise
scientific framework, but that proposes a tool designed to
guarantee ethical and transparent standards at every level while
providing an added layer of support to optometrists throughout the
province," adds André Larente, President of
DIAGNOS.
IRIS-ai is currently being deployed in all of
Quebec and will be gradually introduced to all 150 stores in the
rest of Canada.
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
About IRISIRIS was founded in
1990 in Quebec. Over the years, IRIS has evolved into the largest
network of optometrists, opticians, and ophthalmologists operating
under the same banner across Canada. The company's locations
combine clinical optometry and optical retail to provide a unique
concept and a commitment to offering superior eye care products and
services.
Additional information is available at
www.iris.ca or on their LinkedIn page.
For further information about this Press
Release, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450
678-8882, ext. 224Email: alarente@diagnos.com
Jennifer AhkenEGS PR, responsible of Media
Inquiries for IRIS, The Visual GroupTel: 514-952-2072Email:
ja@egspr.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1e8da027-6593-4a70-b14c-f4756446b2b7
Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025